On August 9, CCTV’s “Morning News” (Zhao Wen Tian Xia) broadcast a special feature highlighting breakthroughs in the localization of Sichuan’s nuclear medicine industry, with a core focus on the accelerating development of an independent and self-reliant industrial ecosystem in Mianyang. Notably, e-Flash, China’s first independently developed electron radiotherapy system from Zhongjiu Flash under Changhong Holding Group, was successfully included in the fast-track review and approval pathway for world-first medical devices. On July 29, it officially entered the Special Review Procedure for Innovative Medical Devices administered by the Center for Medical Device Evaluation of the National Medical Products Administration (NMPA). These dual fast-track pathways significantly accelerate the device’s registration and commercial launch, demonstrating authoritative national recognition for its technological innovation and value.

In an interview with CCTV, Yang Jun, Deputy Secretary of the Party Committee and General Manager of Changhong Holding Group as well as Chairman of Zhongjiu Flash, elaborated on the core advantages of the system. While conventional radiotherapy typically requires nearly 30 fractions with each session lasting several minutes to tens of minutes, FLASH radiotherapy requires only around three fractions, completing single-session irradiation in under one second. While efficiently eliminating tumor cells, it substantially reduces radiation-induced toxic side effects on surrounding normal tissues.The economic advantages are equally compelling. Compared to conventional radiotherapy, which generally totals tens of thousands to hundreds of thousands of yuan, the estimated total treatment cost for FLASH radiotherapy is merely 10,000 to 30,000 yuan, significantly easing the financial burden on cancer patients.

On the technological frontier, the overall R&D progress of Changhong Zhongjiu Flash’s e-Flash Ultra-High Dose Rate Electron Ray Radiotherapy System is keeping pace with leading international counterparts, with plans to initiate large-scale clinical trials by the end of 2026. Concurrently, the world’s first X-Flash radiotherapy device tailored for deep-seated tumors has passed national type inspection and is methodically advancing preclinical validation. Taking a decisive global lead in technological capabilities, this breakthrough fundamentally resolves the long-standing industry challenge of relying on imported high-end radiotherapy equipment, empowering China to build an independent and self-reliant industrial ecosystem in nuclear medicine.

Leveraging Sichuan’s rich nuclear industry heritage and strong support from provincial major science and technology projects, Changhong Zhongjiu Flash has forged a comprehensive full-chain innovation pathway spanning fundamental research, independent development of core components, complete-system engineering, and clinical translation, achieving 100% self-reliance across its three core modules. Looking ahead, the company will coordinate closely with medical products regulatory authorities to advance evaluation and review procedures, accelerating clinical trials and product registration. This will expedite the deployment of China’s domestically developed, original FLASH radiotherapy technology across healthcare institutions, benefiting cancer patients widely and establishing a signature industrial showcase for new quality productive forces in Sichuan.